Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481839 | 0.84 | RECQL (0.67) | RECQLHPGDMEN1KMT2ARAB9A | |
| SCHEMBL4024534 | 0.83 | HPGD (0.76) | RECQLHPGDMEN1KMT2ARAB9A | |
| SCHEMBL15653450 | 0.82 | MEN1 (0.65) | RECQLHPGDMEN1KMT2ARAB9A | |
| SCHEMBL3915837 | 0.76 | KDM2B (0.50) | RECQLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3712697 | 0.75 | MEN1 (0.56) | RECQLHPGDMEN1KMT2ARAB9A | |
| SCHEMBL3281691 | 0.74 | HPGD (0.71) | HPGDMEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL18131039 | 0.74 | MEN1 (0.62) | RECQLHPGDMEN1KMT2ARAB9A | |
| SCHEMBL13917041 | 0.73 | POLB (0.77) | RECQLHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL17504554 | 0.73 | MEN1 (0.65) | HPGDMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14448884 | 0.72 | MEN1 (0.60) | RECQLHPGDMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | RECQL 3362/4885HPGD 2525/4885MEN1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.